NEPG(000597) 中国经济网·2024-11-11 23:21Core Insights - Northeast Pharmaceutical has signed a cash acquisition agreement to purchase 70% of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately 187 million yuan, marking a strategic entry into the specific cell immunotherapy sector [1][2] - Dingcheng Peptide Source, established in 2014, has developed a robust core technology platform for TCR-T, TCR protein drugs, and CAR-T cell therapy products, focusing on solid tumor cell treatment [1][2] Group 1: Acquisition Details - The acquisition allows Northeast Pharmaceutical to quickly enter the specific cell immunotherapy market, which is a rapidly evolving area in the pharmaceutical industry [1] - Dingcheng Peptide Source has developed over ten cell therapy products targeting various cancers, including pancreatic cancer and colorectal cancer, with a focus on specific mutations [2] Group 2: Product Pipeline and Future Prospects - The company has received clinical trial approval for its DCTY1102 injection, which is expected to be the first TCR-T cell drug targeting KRASG12D to enter Phase I clinical research in China [2] - Northeast Pharmaceutical views this acquisition as a significant opportunity to leverage Dingcheng Peptide Source's research capabilities and mature development team to enhance its position in the biopharmaceutical sector [3]